NCT05636215 2025-03-20A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid TumorsInnovent Biologics (Suzhou) Co. Ltd.Phase 1/2 Recruiting368 enrolled